

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>MJALLI ADNAN M M</u> (Last) (First) (Middle) <u>C/O TRANSTECH PHARMA, INC.</u> <u>4170 MENDENHALL OAKS PARKWAY, SUITE 110</u> (Street) <u>HIGH POINT NC 27265</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>SIGA TECHNOLOGIES INC [SIGA]</u> 3. Date of Earliest Transaction (Month/Day/Year) <u>09/30/2009</u> 4. If Amendment, Date of Original Filed (Month/Day/Year) <u>10/02/2009</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	--	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, par value \$0.0001 per share ("Common Stock")	09/30/2009		X		1,845,396	A	\$1.8784	4,317,618	I	by TransTech Pharma, Inc. ⁽²⁾
Common Stock	09/30/2009		F		444,666	D	\$7.8	3,872,952	I	by TransTech Pharma, Inc. ⁽²⁾
Common Stock	09/30/2009		S		3,851,969 ⁽¹⁾	D	\$6.24	20,983	I	by TransTech Pharma, Inc. ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrant (right to buy)	\$1.8784	09/30/2009		X			1,845,396	01/08/2004	01/08/2011	Common Stock	1,845,396	\$0	0	I	By TransTech Pharma, Inc. ⁽²⁾

Explanation of Responses:

1. On September 30, 2009, TransTech Pharma, Inc. sold 3,851,969 shares of Common Stock in a privately negotiated transaction to STH Partners, L.P.
2. The shares of Common Stock and the warrants were beneficially owned by TransTech Pharma, Inc. The reporting person is the President, Chief Executive Officer and a director of TransTech Pharma, Inc. The reporting person disclaims beneficial ownership of the securities beneficially owned by TransTech Pharma, Inc. except to the extent of his pecuniary interest therein.

Remarks:

This amendment is filed to restate the original Form 4. The number of shares shown in this restated Form 4 reflects an anti-dilution adjustment made pursuant to the terms of the SIGA Technologies, Inc. ("SIGA") warrant disclosed in Table II of the original Form 4 and this restated Form 4. On September 28, 2010, SIGA announced a restatement of its financial statements in connection with a failure by SIGA to account for anti-dilution adjustments in certain warrants (including the warrants referenced in Table II). SIGA did not timely advise the reporting persons of the effect of the anti-dilution adjustment, which was triggered before the date of the original Form 4 and which resulted in the issuance of an additional 20,983 shares of Common Stock to TransTech Pharma, Inc. as a result of the exercise of the warrants referenced in Table II. See SIGA's Current Report on Form 8-K filed on September 28, 2010 for more information

Adnan M. M. Mjalli 10/22/2010
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.